Cell-free DNA fragment patterns in early pregnancy may help predict adverse outcomes in patients with immune-mediated ...
PLC (AIM: 4BB), a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), ...
FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free DNA technology. This revolutionary technology ...
A new blood test has an 80% accuracy in predicting preterm preeclampsia, according to a study published today, Feb. 12, in the journal Nature Medicine. The condition, which results in over 70,000 ...
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...
Continued innovation of proprietary cell-free cloning technology has improved synthesis success rates, enabling pricing as low as $0.15 per base pair. SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a ...
When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...
An Austin-based oncologist and breast cancer specialist explains the test and an important caveat about detecting cancer ...
Under this agreement, Genezen, an Ampersand Capital Partners portfolio company, will have access to 4basebio's synthetic DNA, specifically developed for viral vector applications. Additionally, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results